Lunai Bioworks Inc. (RENB)
Lunai Bioworks Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Los Angeles, CA, US. The stock last traded at $1.42, up 0.00% on the session, giving a market capitalisation of $32.9M. On trailing twelve-month figures it carries a trailing P/E of -1.73, a net margin of -66490.4%. Its beta of 0.53 implies it has historically moved less than the broad market.
Lunai Bioworks, Inc. functions as a pre-clinical stage biotechnology enterprise, concentrating its efforts on pioneering genetically modified cell and immunotherapeutic platforms. These advanced technologies are aimed at providing treatments for a range of infectious diseases and oncological conditions. The company's development pipeline features several candidates, specifically ENOB-HV-01, ENOB-HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. Founded on January 18, 2011, by Rene Sindlev and Serhat Gumrukcu, Lunai Bioworks maintains its corporate base in Los Angeles, California.
Lunai Bioworks Inc. is most often compared with the following Healthcare names: